All Articles

A Kansas City CCRC's pivot from hefty entrance fees to a rental model reveals a strategic play by new owner Lapis Advisers, a blueprint for the industry.

Air India is using AI to ask passengers to switch flights for perks. It's a key part of its massive turnaround, turning overbooking from a headache into a choice.

A landmark study proves the link between environmental action and financial performance is not direct, but flows through a powerful new channel: consumer sales.

Advanced Flower Capital's Q2 saw Net Asset Value rise, thanks to a savvy share buyback. But a drop in net investment income reveals a complex transition.

A Kansas health plan reports near-perfect member satisfaction. But what do these numbers truly reveal about the future of long-term care and the push for data-driven dignity?

Abeona Therapeutics celebrates rising sales for its life-changing RDEB therapy, ZEVASKYN. But behind the numbers lies a story of manufacturing hurdles and mounting debt.

As Indonesia Energy Corp drills its K-29 well, we explore the strategy behind the spin. Is this about barrels of oil or building investor confidence?

Q2 data reveals a stark divergence: private markets show steady, earnings-driven growth while public markets chase AI hype. But beneath the surface, a new era of selectivity emerges.

NeuPath Health's Q2 results show headline declines, but a deeper look reveals strong organic growth from record patient visits and strategic expansion.

Revenue is down, but Bragg Gaming's margins are up. A new chairman, a major acquisition, and deep cuts signal a high-stakes bet on a leaner future.

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

MSG Sports posts record profits fueled by a Knicks NBA title, but the real story is the strategic gamble to split its empire, creating long-term risks.

PO Wealth Sharing Group claims 200,000 users and a global footprint. But beneath the surface of this fintech success story lies a troubling pattern.

The FDA is betting on AI to manage chronic illness. Cadence's new pilot for its hypertension software could rewrite the rules for digital health regulation.

A new partnership between Flip Electronics and Vishay confronts the growing crisis of component obsolescence, promising a secure, authorized channel for legacy parts.

Facing a 'going concern' warning, Pulmatrix abandons its drug pipeline for a reverse merger, betting its survival on the high-risk field of longevity science.

ImpactFactory.ai launches a platform integrating 25+ AI engines to automate marketing, promising to democratize advertising. But what does this mean for the human creative?

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

With a giant copper resource, Minsud Resources uses a clever partnership with South32 to fund a 10,500m drill program while preserving capital.

A Washington nonprofit reports a stunning 6% recidivism rate, far below national averages. We dissect the model combining aerospace manufacturing with social reform.